LivaNova PLC $LIVN Shares Purchased by Deutsche Bank AG

Key Points

• Deutsche Bank AG significantly increased its holdings in LivaNova PLC by 84.7% in Q1, now owning 90,333 shares valued at approximately $3.55 million.
• Institutional investors dominate LivaNova's ownership, controlling 97.64% of the stock, with notable increases from firms like Vanguard and Capital Research.
• LivaNova recently reported earnings of $1.05 EPS, exceeding estimates and indicating a 10.6% revenue growth compared to the previous year.

Deutsche Bank AG lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 84.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 90,333 shares of the company's stock after purchasing an additional 41,428 shares during the period. Deutsche Bank AG owned about 0.17% of LivaNova worth $3,548,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC increased its stake in shares of LivaNova by 2,299.7% during the first quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock worth $344,000 after purchasing an additional 8,394 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of LivaNova during the fourth quarter worth about $2,772,000. Envestnet Asset Management Inc. increased its stake in shares of LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after purchasing an additional 5,850 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its position in LivaNova by 147.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company's stock worth $4,582,000 after acquiring an additional 58,911 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its position in LivaNova by 148.5% during the fourth quarter. Two Sigma Advisers LP now owns 214,545 shares of the company's stock worth $9,936,000 after acquiring an additional 128,200 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Trading Up 5.8%

NASDAQ:LIVN traded up $3.04 on Friday, hitting $55.90. The stock had a trading volume of 728,016 shares, compared to its average volume of 806,134. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of -14.37 and a beta of 0.92. The company has a fifty day moving average price of $46.42 and a two-hundred day moving average price of $43.03. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $57.35.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. The company had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. LivaNova's revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.93 EPS. Equities research analysts expect that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LIVN has been the topic of a number of recent research reports. Robert W. Baird boosted their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research report on Tuesday, May 20th. Barclays boosted their price target on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research report on Thursday. Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, Needham & Company LLC restated a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $59.71.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.